This is a working overview of nuclear receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-25. Anything still debated is marked as such rather than presented as settled.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Thirty radioisotopes of protactinium have been discovered, ranging from 210Pa to 239Pa. The most stable are 231Pa with a half-life of 32,650 years, 233Pa with a half-life of 26.975 days, and 230Pa with a half-life of 17.4 days. All other isotopes have half-lives shorter than 1.6 days, and the majority of these have half-lives less than 1.8 seconds. Protactinium also has six nuclear isomers, with the most stable being 234mPa (half-life 1.159 minutes). The primary decay mode for the most stable isotope 231Pa and lighter isotopes (210Pa to 227Pa) is alpha decay, producing isotopes of actinium. The primary decay mode for 228Pa to 230Pa is electron capture or beta plus decay, producing isotopes of thorium, while the primary decay mode for the heavier isotopes (232Pa to 239Pa) is beta decay, producing isotopes of uranium.
Methylphenidate is a psychostimulant drug that is often used in the treatment of ADHD and narcolepsy and occasionally to treat obesity in combination with diet restraints and exercise. Its effects at therapeutic doses include increased focus, increased alertness, decreased appetite, decreased need for sleep and decreased impulsivity. Methylphenidate is not usually used recreationally, but when it is used, its effects are similar to those of amphetamines. Methylphenidate acts as a norepinephrine–dopamine reuptake inhibitor (NDRI), by blocking the norepinephrine transporter (NET) and the dopamine transporter (DAT). Methylphenidate has a higher affinity for the dopamine transporter than for the norepinephrine transporter, and so its effects are mainly due to elevated dopamine levels caused by the inhibited reuptake of dopamine, however increased norepinephrine levels also contribute to various of the effects caused by the drug. Methylphenidate is sold under a number of brand names including Ritalin. Other versions include the long lasting tablet Concerta and the long lasting transdermal patch Daytrana.
Behr was named political commentator of the year at the 2014 Comment Awards; in 2019, he was shortlisted for same award again. Before becoming a journalist, Behr worked as a political risk analyst reporting on countries of the former Soviet Union.Since 2020 he has presented Politics on the Couch, an occasional podcast about the psychology of politics. Daniel Ben-Ami, journalist and author; has written on economic development, the world economy, financial markets and investment funds; has also used pseudonym Daniel Nassim. His work has appeared in Jewish Chronicle, Financial Times, The Guardian, The Independent, Prospect, The Sunday Telegraph and The Sunday Times and in the successor to Living Marxism, Spiked. Roger Bennett (journalist) (born 14 September 1970); journalist for Tablet (magazine) broadcaster, podcaster, and filmmaker; co-hosts Men in Blazers podcast and television show alongside Michael Davies; author Reborn in the USA: An Englishman's Love Letter to his Chosen Home; married to Vanessa Kroll, daughter of Kroll Inc. founder Jules Kroll; his brother-in-law is comedian Nick Kroll. Bennett is Jewish. Chaim Bermant (1929–1998), journalist and novelist.
== Factors affecting ion exchange resin efficiency == The efficiency of ion exchange resins is influenced by a combination of physical, chemical, and operational factors. These variables determine how effectively the resin can exchange ions, maintain selectivity, and preserve its structural integrity over time. The structural properties of the resin are fundamental to its performance. Attributes such as particle size, internal porosity, and the degree of cross-linking control the accessibility of exchange sites. Smaller particles tend to offer faster ion exchange due to greater surface area, although they can also lead to increased resistance to flow in packed bed systems. Temperature is another key factor. In general, higher temperatures accelerate ion mobility and enhance exchange kinetics. However, prolonged exposure to elevated temperatures can degrade the resin's polymer matrix or functional groups, particularly in weakly acidic or basic resins. There are however, resins rated for higher temperatures (up to 120 °C) which employ reinforced polymer backbones to withstand thermal stress on the system. The pH of the solution directly affects the ionization state of both the resin and the solutes. While strong acid and strong base resins maintain their functionality across a wide pH range, weak resins may lose efficiency outside their optimal pH window. The pH also influences the speciation of certain ions, impacting their affinity for the resin. Ionic concentration determines the driving force for ion exchange.
Sources: en.wikipedia.org
=== Selected papers === O. C. Sandall, C. J. King & C. R. Wilke, "The Relationship between Transport Properties and Rates of Freeze Drying of Poultry Meat", AIChE Jour., 13, 428-438 (1967). S. K. Chandrasekaran & C. J. King, "Multicomponent Diffusion and Vapor-Liquid Equilibria of Dilute Organic Components in Aqueous Sugar Solution", AIChE Jour., 18, 513-520 (1972). R. J. Bellows & C. J. King, "Freeze-drying of Aqueous Solutions: Maximum Allowable Operating Temperature", Cryobiology, 9, 559-561 (1972). T. G. Kieckbusch & C. J. King, "Volatiles Loss during Atomization in Spray Drying", AIChE Jour., 21, 718-725 (1980). G. E. Downton, J. L. Flores-Luna & C. J. King, "Mechanism of Stickiness in Hygroscopic, Amorphous Powders", Ind. Eng. Chem. Fundamentals, 21, 447-451 (1982). A. S. Kertes & C. J. King, "Extraction Chemistry of Fermentation Product Carboxylic Acids", Biotechnol. & Bioengg., 28, 269-282 (1986). C. J. King, "Separation Processes Based on Reversible Chemical Complexation", Ch. 15 in R. W. Rousseau, ed., Handbook of Separation Process Technology, pp. 760–774, Wiley, 1987. T. M. El-Sayed, D. A. Wallack & C. J. King, "Changes in Particle Morphology during Drying of Drops", Parts I & II, Ind. Engg. Chem. Research, 29, 2346-2354 (1990). C. J. King, "Amine-based System for Carboxylic Acid Recovery: Tertiary Amines and the proper choice of diluent allow extraction and recovery from water", CHEMTECH, 285-291 (May, 1992). L. A. Tung & C. J. King, "Sorption and Extraction of Lactic and Succinic Acids at pH>pKa1", Parts I & II, Ind. Engg. Chem. Res., 34, 3217-3229 (1994).
By the 15th century, tulips were among the most prized flowers; becoming the symbol of the later Ottomans. Tulips were cultivated in Byzantine Constantinople as early as 1055 but they did not come to the attention of Northern Europeans until the sixteenth century, when Northern European diplomats to the Ottoman court observed and reported on them. They were rapidly introduced into Northern Europe and became the subject of an investment bubble during the Dutch tulip mania of 1634–1637. Tulips were frequently depicted in Dutch Golden Age paintings, and have become associated with the Netherlands, the major producer for world markets, ever since. In the seventeenth-century Netherlands, during the time of the tulip mania, an infection of tulip bulbs by the tulip breaking virus created variegated patterns in the tulip flowers that were much admired and valued. While truly broken tulips are not cultivated anymore, the closest available specimens today are part of the group known as the Rembrandts – so named because Rembrandt painted some of the most admired breaks of his time. Breeding programmes have produced thousands of hybrid and cultivars in addition to the original species (known in horticulture as botanical tulips). They are popular throughout the world, both as ornamental garden plants and as cut flowers.
==== Post-SSRI sexual dysfunction ==== Post-SSRI sexual dysfunction (PSSD) refers to a set of symptoms reported by some people who have taken SSRIs or other serotonin reuptake-inhibiting (SRI) drugs, in which sexual dysfunction symptoms persist for at least three months after ceasing to take the drug. The status of PSSD as a legitimate and distinct pathology is contentious; several researchers have proposed that it be recognized as a separate phenomenon from more common SSRI side effects. The reported symptoms of PSSD include reduced sexual desire or arousal, erectile dysfunction in males or loss of vaginal lubrication in females, persistent premature ejaculation (even in patients without a previous history of the condition), difficulty having an orgasm or loss of pleasurable sensation associated with orgasm, and a reduction or loss of sensitivity in the genitals or other erogenous zones. Additional non-sexual symptoms are also commonly described, including emotional numbing, anhedonia, depersonalization or derealization, and cognitive impairment. The duration of PSSD symptoms appears to vary among patients, with some cases resolving in months and others in years or decades; one analysis of patient reports submitted between 1992 and 2021 in the Netherlands listed a case which had reportedly persisted for 23 years.
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.